Daraxonrasib was shown to have “landscape-changing” results in extending life expectancy, according to the American Society ...

Investigational apitegromab -- a selective myostatin activation inhibitor -- effectively preserved lean mass when combined with tirzepatide (Zepbound) in a randomized phase II trial, suggesting it ...

A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He ...

Most adult Americans take at least one prescription drug, and for too many, getting that prescription filled means battling the very system that's supposed to help them. Insurance denials have become ...

Developed by the British pharmaceutical giant Astra Zeneca, saracatinib, also called AZDO5030, did not prove effective in trials in fighting the tumors it was hoped it would treat. But scientists at ...